Filing Flows › Companies › Zevra Therapeutics › Timeline
Zevra Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+27.4% to $11.59
Zevra Therapeutics (ZVRA) stock rose 27% over the last 252 sessions, to $11.59. On the way it reported 4 quarters, its insiders filed 1 open-market trade and 3 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings | Earnings: beat the EPS estimate by 35.3% | +1.6% (+1.3% vs SPY) | — | — |
| Oct 12, 2026 | Form 144 | Form 144: Neil F McFarlane plans to sell $228K | −0.6% (−0.6% vs SPY) | −13.6% (−11.6% vs SPY) | — |
| Aug 14, 2026 | Form 144 | Form 144: Rahsaan Thompson plans to sell $477K | +1.2% (+1.4% vs SPY) | +6.2% (+8.1% vs SPY) | +7.5% (+9.7% vs SPY) |
| Aug 10, 2026 | Insider sale | Watton Corey Michael sold $138K | −0.7% (−0.7% vs SPY) | −2.1% (−2.5% vs SPY) | +9.2% (+10.2% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 41.5% | +0.1% (+0.3% vs SPY) | +7.5% (+7.6% vs SPY) | +15.6% (+16.4% vs SPY) |
| Jul 8, 2026 | Form 144 | Form 144: John Bode plans to sell $156K | +2.1% (+2.4% vs SPY) | −10.0% (−10.6% vs SPY) | −31.6% (−34.5% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 114.9% | +5.9% (+4.5% vs SPY) | +4.1% (+2.1% vs SPY) | +5.1% (+0.6% vs SPY) |
| Mar 16, 2026 | 8-K | Material definitive agreement | −1.1% (−2.1% vs SPY) | −7.8% (−6.0% vs SPY) | −1.9% (−7.0% vs SPY) |
| Mar 9, 2026 | 8-K | Directors and officers: departures, appointments, pay | +19.3% (+19.4% vs SPY) | +7.9% (+9.3% vs SPY) | +5.0% (+5.1% vs SPY) |
| Mar 9, 2026 | Earnings | Earnings: beat the EPS estimate by 322.2% | +1.5% (+0.7% vs SPY) | +10.6% (+12.1% vs SPY) | +7.5% (+9.2% vs SPY) |
| Dec 17, 2025 | 8-K | Directors and officers: departures, appointments, pay | −0.1% (−0.9% vs SPY) | +6.3% (+3.3% vs SPY) | +10.6% (+9.4% vs SPY) |
| Dec 2, 2025 | 8-K | Directors and officers: departures, appointments, pay | −2.1% (−2.2% vs SPY) | +5.1% (+4.6% vs SPY) | +7.2% (+6.7% vs SPY) |
| Nov 20, 2025 | 8-K | Directors and officers: departures, appointments, pay | −5.1% (−6.1% vs SPY) | −7.1% (−11.7% vs SPY) | −5.7% (−10.8% vs SPY) |
Insiders’ record here
In the year on the chart, Zevra Therapeutics' insiders reported 0 open-market buys ($0) and 1 sale ($138K).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Zevra Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.